Biotechnology
Last Week in Biotech: Late-Stage Clinical Wins, Multi-Billion Strategic Alliances, and Precision Epigenomic Editing (2026-11-17)
Key biotech developments: Sellas’ Phase 3 AML win, CG Oncology’s oncolytic virus data, Eli Lilly’s $5.9B Stipple deal, J&J’s $2.2B Ollin acquisition, and breakthrough CRISPR enhancer activation.